Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
  • 0 views
  • 02 Jun, 2021
  • 395 locations
  • 2496 views
  • 28 Jan, 2021
  • 210 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab

androgen
androgen suppression
testosterone
enzalutamide
metastasis
  • 0 views
  • 23 Jun, 2021
  • 12 locations
Investigation of Radium-223 Dichloride (Xofigo) a Treatment That Gives Off Radiation That Helps Kill Cancer Cells Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced

  • 0 views
  • 19 Jun, 2021
  • 145 locations
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).

  • 0 views
  • 23 Jun, 2021
  • 9 locations
Abiraterone Acetate in Combination With Tildrakizumab

The purpose of this study is to find out the side effects and safety of a combination of the anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate in men

  • 0 views
  • 27 Jan, 2021
  • 7 locations
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

The aim of this trial is to evaluate the Drug-Drug interaction with Abiraterone combined with SHR3162 in the Metastatic Castration Resistant Prostate Cancer Patients.

  • 0 views
  • 23 Jan, 2021
  • 1 location
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with abiraterone acetate 1000 mg daily plus prednisone 5

gonadotropin releasing hormone
adenocarcinoma
abiraterone
luteinizing hormone
docetaxel
  • 0 views
  • 25 Jan, 2021
  • 1 location
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation

  • 0 views
  • 22 Apr, 2021
  • 1 location
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

adenocarcinoma
onvansertib
conjugated bilirubin
abiraterone
testosterone
  • 1 views
  • 01 Apr, 2021
  • 2 locations